Pierre de Waha
Directeur/Bestuurslid bij Cellaïon SA
Profiel
Pierre de Waha is currently a Director at GreenWatt SA and Cellaïon SA. He is also an Investment Manager at Invest.
BW SA since 2007.
Previously, he worked as an Investment Manager at BNP Paribas Fortis Private Equity Belgium NV.
Actieve functies van Pierre de Waha
Bedrijven | Functie | Begin |
---|---|---|
Invest.BW SA
Invest.BW SA Investment ManagersFinance Societe de Developpement et de Participation du Brabant Wallon SA (Invest.BW) is a private equity and venture capital firm founded in 1987. Invest.BW SA is headquartered in Louvain-la-Neuve. | Private Equity Investor | 01-04-2007 |
GreenWatt SA
GreenWatt SA Electric UtilitiesUtilities GreenWatt SA designs and installs on-site bio-methanization plants. It engages in the provision of renewable energy and recycling solutions for waste bio-methanization cogeneration. The company was founded by Marc-Jean Spiltoir, Patrick Alexandre Thierry Rene van den Broucke, and Therese Marie Wathelet Florence in 2004 and is headquartered in Louvain-la-Neuve, Belgium. | Directeur/Bestuurslid | - |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Pierre de Waha
Bedrijven | Functie | Einde |
---|---|---|
BNP Paribas Fortis Private Equity Belgium NV
BNP Paribas Fortis Private Equity Belgium NV Investment ManagersFinance BNP Paribas Fortis Private Equity Belgium NV is a Private Equity/Venture Capital firm, a subsidiary of BNP Paribas Fortis SA/NV founded in 1981. BNP Paribas Fortis Private Equity Belgium NV is headquartered in Brussels. | Private Equity Investor | 20-02-2007 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
BNP Paribas Fortis Private Equity Belgium NV
BNP Paribas Fortis Private Equity Belgium NV Investment ManagersFinance BNP Paribas Fortis Private Equity Belgium NV is a Private Equity/Venture Capital firm, a subsidiary of BNP Paribas Fortis SA/NV founded in 1981. BNP Paribas Fortis Private Equity Belgium NV is headquartered in Brussels. | Finance |
Invest.BW SA
Invest.BW SA Investment ManagersFinance Societe de Developpement et de Participation du Brabant Wallon SA (Invest.BW) is a private equity and venture capital firm founded in 1987. Invest.BW SA is headquartered in Louvain-la-Neuve. | Finance |
GreenWatt SA
GreenWatt SA Electric UtilitiesUtilities GreenWatt SA designs and installs on-site bio-methanization plants. It engages in the provision of renewable energy and recycling solutions for waste bio-methanization cogeneration. The company was founded by Marc-Jean Spiltoir, Patrick Alexandre Thierry Rene van den Broucke, and Therese Marie Wathelet Florence in 2004 and is headquartered in Louvain-la-Neuve, Belgium. | Utilities |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Health Technology |